PMID- 28103249
OWN - NLM
STAT- MEDLINE
DCOM- 20170807
LR  - 20181113
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 1
DP  - 2017
TI  - The Green Tea Catechin Epigallocatechin Gallate Ameliorates Graft-versus-Host 
      Disease.
PG  - e0169630
LID - 10.1371/journal.pone.0169630 [doi]
LID - e0169630
AB  - Allogeneic hematopoetic stem cell transplantation (allo-HSCT) is a standard 
      treatment for leukemia and other hematologic malignancies. The major complication 
      of allo-HSCT is graft-versus-host-disease (GVHD), a progressive inflammatory 
      illness characterized by donor immune cells attacking the organs of the 
      recipient. Current GVHD prevention and treatment strategies use immune 
      suppressive drugs and/or anti-T cell reagents these can lead to increased risk of 
      infections and tumor relapse. Recent research demonstrated that epigallocatechin 
      gallate (EGCG), a component found in green tea leaves at a level of 25-35% at dry 
      weight, may be useful in the inhibition of GVHD due to its immune modulatory, 
      anti-oxidative and anti-angiogenic capacities. In murine allo-HSCT recipients 
      treated with EGCG, we found significantly reduced GVHD scores, reduced target 
      organ GVHD and improved survival. EGCG treated allo-HSCT recipients had 
      significantly higher numbers of regulatory T cells in GVHD target organs and in 
      the blood. Furthermore, EGCG treatment resulted in diminished oxidative stress 
      indicated by significant changes of glutathione blood levels as well as 
      glutathione peroxidase in the colon. In summary, our study provides novel 
      evidence demonstrating that EGCG ameliorates lethal GVHD and reduces GVHD-related 
      target organ damage. Possible mechanisms are increased regulatory T cell numbers 
      and reduced oxidative stress.
FAU - Westphal, Sabine
AU  - Westphal S
AD  - Department of Hematology, Oncology and Tumorimmunology, Charite Campus Virchow, 
      Berlin, Germany.
FAU - McGeary, Aleixandria
AU  - McGeary A
AD  - Department of Hematology, Oncology and Tumorimmunology, Charite Campus Virchow, 
      Berlin, Germany.
FAU - Rudloff, Sandra
AU  - Rudloff S
AD  - Department of Hematology, Oncology and Tumorimmunology, Charite Campus Virchow, 
      Berlin, Germany.
FAU - Wilke, Andrea
AU  - Wilke A
AD  - Department of Hematology, Oncology and Tumorimmunology, Charite Campus Virchow, 
      Berlin, Germany.
FAU - Penack, Olaf
AU  - Penack O
AD  - Department of Hematology, Oncology and Tumorimmunology, Charite Campus Virchow, 
      Berlin, Germany.
LA  - eng
PT  - Journal Article
DEP - 20170119
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Alkaloids)
RN  - 0 (Antioxidants)
RN  - 0 (Benzodioxoles)
RN  - 0 (Immunologic Factors)
RN  - 0 (Piperidines)
RN  - 0 (Polyunsaturated Alkamides)
RN  - 0 (Tea)
RN  - 8R1V1STN48 (Catechin)
RN  - 9IKM0I5T1E (Quercetin)
RN  - BQM438CTEL (epigallocatechin gallate)
RN  - U71XL721QK (piperine)
SB  - IM
MH  - Alkaloids/administration & dosage
MH  - Allografts
MH  - Animals
MH  - Antioxidants/pharmacology
MH  - Benzodioxoles/administration & dosage
MH  - Catechin/administration & dosage/*analogs & derivatives/blood/pharmacology
MH  - Disease Models, Animal
MH  - Female
MH  - Graft Survival/drug effects
MH  - Graft vs Host Disease/drug therapy/metabolism/*prevention & control
MH  - Hematopoietic Stem Cell Transplantation/adverse effects
MH  - Humans
MH  - Immunologic Factors/pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Inbred DBA
MH  - Neovascularization, Pathologic/prevention & control
MH  - Oxidative Stress/drug effects
MH  - Piperidines/administration & dosage
MH  - Polyunsaturated Alkamides/administration & dosage
MH  - Quercetin/administration & dosage
MH  - T-Lymphocytes, Regulatory/drug effects
MH  - Tea/chemistry
PMC - PMC5245838
COIS- The authors have declared that no competing interests exist.
EDAT- 2017/01/20 06:00
MHDA- 2017/08/08 06:00
PMCR- 2017/01/19
CRDT- 2017/01/20 06:00
PHST- 2016/05/04 00:00 [received]
PHST- 2016/12/09 00:00 [accepted]
PHST- 2017/01/20 06:00 [entrez]
PHST- 2017/01/20 06:00 [pubmed]
PHST- 2017/08/08 06:00 [medline]
PHST- 2017/01/19 00:00 [pmc-release]
AID - PONE-D-16-16840 [pii]
AID - 10.1371/journal.pone.0169630 [doi]
PST - epublish
SO  - PLoS One. 2017 Jan 19;12(1):e0169630. doi: 10.1371/journal.pone.0169630. 
      eCollection 2017.